Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (241-250 of 446) with videos related to

Pageof 45
Sort By:
Mayo Clinic Proceedings|July 5, 2022
Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell TherapyNaba Farooqui, Janina Paula T Sy-Go, Jing Miao, et al.
Blood Cancer Journal|April 12, 2022
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantationAbdullah S Al Saleh, Mohammad S Ebraheem, M Hasib Sidiqi, et al.
Bone Marrow Transplantation|April 3, 2022
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosisJoselle Cook, Wilson I Gonsalves, Morie A Gertz, et al.
Blood Cancer Journal|March 21, 2015
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myelomaW I Gonsalves, N Leung, S V Rajkumar, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Blood|January 12, 2012
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsShaji Kumar, Rafael Fonseca, Rhett P Ketterling, et al.
Pageof 45

Showing results (241-250 of 446) with videos related to

Sort By:
Pageof 45
Mayo Clinic Proceedings|July 5, 2022
Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell TherapyNaba Farooqui, Janina Paula T Sy-Go, Jing Miao, et al.
Blood Cancer Journal|April 12, 2022
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantationAbdullah S Al Saleh, Mohammad S Ebraheem, M Hasib Sidiqi, et al.
Bone Marrow Transplantation|April 3, 2022
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosisJoselle Cook, Wilson I Gonsalves, Morie A Gertz, et al.
Blood Cancer Journal|March 21, 2015
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myelomaW I Gonsalves, N Leung, S V Rajkumar, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
American Journal of Hematology|October 13, 2016
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationYi L Hwa, Qian Shi, Shaji K Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen typeEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Blood|January 12, 2012
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsShaji Kumar, Rafael Fonseca, Rhett P Ketterling, et al.
Pageof 45